May 2022

Contents

Editorial

• HTB May 2022 (2 May 2022)

Conference reports

• 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports

• CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

• CROI 2022: Other COVID-19 studies

Antiretrovirals

• FDA approves dispersible dolutegravir/abacavir/3TC for children

• Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits

Coinfections and complications

• Asymptomatic COVID-19 is common in people living with HIV

• Longest COVID-19 infection lasted 505 days in an immunocompromised person in London

• Herd immunity unlikely to control COVID-19: opinion article from US NIAID

• The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19

• Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms

• Two new platform vaccines against COVID-19 report phase 3 results

HIV prevention and transmission

• A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton

• Zimbabwe decriminalises HIV transmission

Cure-related research

• Community webinar series on HIV cure-related cell and gene therapy

Other news

• Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers

PDFs

• HTB: no. 5 (2 May 2022) PDF downloads